A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

NCT06230224 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

216

Enrollment

INDUSTRY

Sponsor class

Conditions

B-Cell Non-Hodgkin Lymphoma (B-NHL)

Interventions

DRUG: Odronextamab
DRUG: Ifosfamide
DRUG: Carboplatin
DRUG: Etoposide
DRUG: Rituximab
DRUG: Dexamethasone
DRUG: Cisplatin
DRUG: Cytarabine
DRUG: Gemcitabine

Sponsor

Regeneron Pharmaceuticals